Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.

Name: Αlpha¹ Rigor Record — Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Item: Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Rating: 96
Author: Αlpha¹

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD, endTB Clinical Trial Team

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.25★ (Strong), 0 critical, 2 high issues for “Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced2 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported Phase 3 randomized non-inferiority trial with rigorous design, clear statistical methods, and comprehensive reporting of ethics, demographics, and outcomes. The main weakness is the lack of a clear data availability statement and code sharing, which is a common but important transparency gap.

Both reviewers agreed on study type (interventional) and on all dimension statuses except minor differences in checklist sub-items (e.g., limitations addressed, regulatory compliance, data availability statement). The synthesis adopted the more specific evidence where available. Non-applicable sub-criteria (e.g., animal-related, cell lines) were excluded. The statistics verification covered only 1 test (hazard ratio) and found it consistent; other statistics were not machine-verified.

5 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites WHO statistics and historical reliance on expert opinion and observational studies, and it references the launch of endTB and other trials. The rationale for comparing five all-oral regimens to the standard of care is clearly linked to the need for shorter, safer, and more effective treatments. The paper does not explicitly discuss limitations of prior research in detail, but the design addresses the lack of randomized evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior observational evidence and the need for randomized trials, and it provides a logical rationale for the study objectives.

Evidence

direct quote[Introduction, paragraph 1]

“Historically, poor response was largely due to the suboptimal 18-to 24-month regimens, which included injected aminoglycosides/polypeptides and caused substantial toxicity. Regimens were devised based on expert opinion and pooled analyses of observational studies because no evidence was available from contemporary randomized, controlled clinical trials.”